Toward improved immunocompetence of adoptively transferred CD8+ T cells

Journal of Clinical Investigation

Volumn 115, Issue 6, 2005, Pages 1467-1469

  Speiser, Daniel E ^a,b   Romero, Pedro ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hopital Orthopedique de la Suisse Romande   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; GRANZYME A; GRANZYME B; HOMING RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 2; PERFORIN; PROTEIN CD62 LIGAND; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; ANTIGEN SPECIFICITY; AUTOTRANSPLANTATION; CELL CULTURE; CELL DIFFERENTIATION; CELL SELECTION; CELL TRANSFER; EFFECTOR CELL; IMMUNOCOMPETENCE; IMMUNOTHERAPY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VACCINATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; MICE; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 20444468823     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI25427     Document Type: Review

References (28)

1. Kolb, H.J., et al. 1990. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:2462-2465.
2. Riddell, S.R., and Greenberg, P.D. 1995. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13:545-586.
3. Roskrow, M.A., et al. 1999. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 91:2925-2934.
4. Yee, C., et al. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U. S. A. 99:16168-16173.
5. Dudley, M.E., et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23:2346-2357.
6. Walter, E.A., et al. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl J. Med. 333:1038-1044.
7. Dudley, M.E., et al. 2001. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24:363-373.
8. Pape, K.A., et al. 1997. Use of adoptive transfer of T-cell-antigen- receptor-transgenic T cell for the study of T-cell activation in vivo. Immunol. Rev. 156:67-78.
9. + T cells. J. Clin. Invest. 115:1616-1626. doi:10.1172/JCI24480.
10. Kägi, D., Ledermann, B., Bürki, K., Zinketnagel, R.M., and Hengartner, H. 1996. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Immunol. 14:207-232.
11. Dailey, M.O., Fathman, C.G., Butcher, E.G., Pillemer, E., and Weissman, I. 1982. Abnormal migration of T lymphocyte clones. J. Immunol. 128:2134-2136.
12. Sprent, J., and Miller, J.F. 1976. Fate of H2-activated T lymphocytes in syngeneic hosts. III. Differentiation into long-lived recirculating memory cells. Cell Immunol. 21:314-326.
13. Crispe, I.N., Moore, M.W., Husmann, L.A., Smith, L., and Bevan, M.J. 1987. Differentiation potential of subsets of CD4-8- thymocytes. Nature. 329:336-339.
14. Zinkernagel, R., et al. 1996. On immunological. memory. Annu. Rev. Immunol. 14:333-367.
15. Sallusto, F., and Lanzavecchia, A, 2001. Exploring pathways for memory T cell generation. J. Clin. Invest. 108:805-806. doi:10.1172/JCI200114005.
16. Kaech, S.M., Wherry, E.J., and Ahmed, R. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:251-262.
17. Masopust, D., and Lefrancois, L. 2003. CD8 T-cell memory: the other half of the story. Microbes. Infect. 5:221-226.
18. Sallusto, F., Geginat, J., and Lanzavecchia, A. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22:745-763.
19. Moskophidis, D., Lechner, F., Pircher, H., and Zinkernagel, R.M. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature. 362:758-761.
20. Zajac, A.J., et al. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205-2213.
21. Kostense, S., et al. 2001. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur. J. Immunol. 31:677-686.
22. Lechner, F., et al. 2000. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191:1499-1512.
23. Lee, P.P., et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677-685.
24. Zippelius, A., et al. 2004. Effector function of human tumor-speciftc CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64:2865-2873.
25. Rufer, N., et al. 1999. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J. Exp. Med. 190:157-167.
26. Douek, D.C., et al. 1998. Changes in thymic function with age and during the treatment of HIV infection. Nature. 396:690-695.
27. Wherry, E.J., et al. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:225-234.
28. Zhang, X., Sun, S., Hwang, I., Tough, D.F., and Sprent, J. 1998. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by TL-15. Immunity. 8:591-599.